C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis

Gui, Xi Yao; Rabkin, Simon W.

doi:10.1007/s11897-022-00584-9

Cited by 12 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, HFpEF patients exhibit more severe endothelial dysfunction, and the NO-sGC-cGMP pathway is less responsive in this group. The distinctions in the NO-sGC-cGMP pathway's functioning between HFrEF and HFpEF patients play a pivotal role in driving the distinct pathological mechanisms observed in these two types of HF (6,7). This might be a potential explanation for the different effects of sGC stimulators in HFpEF and HFrEF.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble guanylate cyclase (sGC) stimulators in heart failure with preserved ejection fraction: a systematic review and meta-analysis

Zhao,

Zang,

Wang

2023

Shock

View full text Add to dashboard Cite

Aims We conducted a systemic review and meta-analysis to evaluate the therapeutic efficacy and safety of soluble guanylate cyclase(sGC) stimulators in patients with heart failure with preserved ejection fraction(HFpEF). Methods We systematically searched PubMed, EMBASE and Cochrane Library databases for original randomized controlled trials comparing sGC stimulators with placebo in HFpEF patients. A random-effects model was applied to evaluate the mortality, quality of life and drug-related adverse events. This meta-analysis is registered in PROSPERO under the number CRD42023457382. Results We included five studies involving 1600 HFpEF patients. Comprehensively, the combined risk ratio (RR) for mortality was not significant(RR(95% CI) = 1.44 (0.71-2.91), p = 0.31). Furthermore, there were no statistically significant differences in the Kansas City Cardiomyopathy Questionnaire (KCCQ) results, including the Clinical Summary Score(CSS) (WMD (95% CI) =0.32( -7.38-8.02), p = 0.94) and the Overall Summary Score(OSS) (WMD (95% CI) = -0.87( -8.87-7.14), P = 0.83). Similarly, there was no significant improvement in the 6-minute walk distance(6MWD) (WMD(95% CI) = -6.22(-18.56-6.12), p = 0.32). Additionally, drug-related adverse events were more common in patients treated with sGC stimulators(RR(95%CI) = 1.63,(1.25-2.14), p < 0.05). Conclusions Oral sGC stimulators do not significantly improve mortality outcomes, functional capacity and quality of life in HFpEF patients but are associated with increased drug-related adverse events. Therefore, we should consider using sGC stimulators in HFpEF patients carefully.

show abstract

Section: Discussionmentioning

confidence: 99%

“…On the other hand, HFpEF patients have significantly higher serum NO levels than HFpEF, with a more pronounced decline in NO-sGC-cGMP pathway activity. The sGC stimulators can directly target sGC, leading to therapeutic benefits (6,7). Vericiguat has been recommended in the latest American guideline for HFrEF patients (8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Soluble guanylate cyclase (sGC) stimulators in heart failure with preserved ejection fraction: a systematic review and meta-analysis

Zhao,

Zang,

Wang

2023

Shock

View full text Add to dashboard Cite

show abstract

“…By way of a systemic inflammation issue, the mediator TNFα can increase fat mass and insulin resistance (Raza et al, 2020;Parcha et al, 2022), thereafter triggering obesity. At the same time, the IL-6 mediator augmented the transcript of elevation-sensitivity CRP (C-reactive protein), which is principally related to abdominal obesity (Gui and Rabkin, 2022). Furthermore, the anti-inflammatory action of curcumin might be associated with the suppression of PAI-1, MCP-1, TNFα genes (Tyszkowski and Mehrzad, 2023) and augments the synthesis of adipocytes-linked anti-inflammatory influence recognized as adiponectin (Tyszkowski and Mehrzad, 2023).…”

Section: Curcumin and Obesitymentioning

confidence: 99%

The relationship between dietary curcumin supplementation and metabolic syndrome – A Review

El‐Hack

Alazragi

Khafaga

et al. 2024

Annals of Animal Science

View full text Add to dashboard Cite

Metabolic syndrome is one of the utmost frequent diseases with the augmentation of the fast oscillations in societies’ lifestyles. On the other side, various medicinal plants have recently been extensively used for plentiful therapeutics. Among these, curcumin and turmeric are the main components derivative from the rhizome of plants, with significant effects on preventing metabolic syndromes. Due to their antioxidant and anti-inflammatory activities, the biological activities of turmeric and its bioactive element, curcumin, have antidiabetic properties via augmenting insulin release and anti-hyperlipidemia effects via enhancing fatty acids uptake, anti-obesity properties via declining lipogenesis, and antihypertensive properties via augmenting nitric oxide synthesis. Moreover, the dietary presence of turmeric and its bioactive element, curcumin, significantly affected poultry productivity, health and welfare. According to human and animal trials, turmeric or curcumin has important values as dietary supplementation and complementary therapy in some metabolic syndromes. This scenario highpoint on the potential effects of curcumin (turmeric) on poultry health and its role in complementary therapy in metabolic syndrome. Additional high-quality clinical trial investigations are required to establish the clinical efficiency of the curcumin complement confidently.

show abstract

“…TMAO is a marker of HF as serum levels of TMAO are higher among patients with HF than those without HF, but, importantly, this does not discriminate HFpEF from HFrEF. Thus, TMAO cannot be considered a unique marker of HFpEF but can help identify high-risk patients when associated with other markers [67]. Acute HF is another important HF setting, for which TMAO is essential as a prognostic marker: in a study by Suzuki et al, the authors reported that the detection of elevated TMAO levels in patients admitted to the hospital for acute HF correlated with an increase in rehospitalization at 1 year and mortality.…”

Section: Tmao: a Prognostic Marker Of Hfmentioning

confidence: 99%

Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?

Belli

Barone

Longo

et al. 2023

IJMS

View full text Add to dashboard Cite

A great deal of evidence has revealed an important link between gut microbiota and the heart. In particular, the gut microbiota plays a key role in the onset of cardiovascular (CV) disease, including heart failure (HF). In HF, splanchnic hypoperfusion causes intestinal ischemia resulting in the translocation of bacteria and their metabolites into the blood circulation. Among these metabolites, the most important is Trimethylamine N-Oxide (TMAO), which is responsible, through various mechanisms, for pathological processes in different organs and tissues. In this review, we summarise the complex interaction between gut microbiota and CV disease, particularly with respect to HF, and the possible strategies for influencing its composition and function. Finally, we highlight the potential role of TMAO as a novel prognostic marker and a new therapeutic target for HF.

show abstract

C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis

Cited by 12 publications

References 59 publications

Soluble guanylate cyclase (sGC) stimulators in heart failure with preserved ejection fraction: a systematic review and meta-analysis

Soluble guanylate cyclase (sGC) stimulators in heart failure with preserved ejection fraction: a systematic review and meta-analysis

The relationship between dietary curcumin supplementation and metabolic syndrome – A Review

Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?

Contact Info

Product

Resources

About